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Abstract
The presence of the conceptus in uterine cavity necessitates an elaborate network of interactions between the implanting
embryo and a receptive endometrial tissue. We believe that embryo-derived signals play an important role in the
remodeling and the extension of endometrial receptivity period. Our previous studies provided original evidence that
human Chorionic Gonadotropin (hCG) modulates and potentiates endometrial epithelial as well as stromal cell
responsiveness to interleukin 1 (IL1), one of the earliest embryonic signals, which may represent a novel pathway by
which the embryo favors its own implantation and growth within the maternal endometrial host. The present study was
designed to gain a broader understanding of hCG impact on the modulation of endometrial cell receptivity, and in
particular, cell responsiveness to IL1 and the acquisition of growth-promoting phenotype capable of receiving, sustaining,
and promoting early and crucial steps of embryonic development. Our results showed significant changes in the expression
of genes involved in cell proliferation, immune modulation, tissue remodeling, apoptotic and angiogenic processes. This
points to a relevant impact of these embryonic signals on the receptivity of the maternal endometrium, its adaptation to the
implanting embryo and the creation of an environment that is favorable for the implantation and the growth of this latter
within a new and likely hostile host tissue. Interestingly our data further identified a complex interaction between IL1 and
hCG, which, despite a synergistic action on several significant endometrial target genes, may encompass a tight control of
endogenous IL1 and extends to other IL1 family members.
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Introduction
Embryonic implantation and establishment of successful preg-
nancy require a dynamic process of interactions between the
embryo and a receptive maternal endometrium. This embryo/
maternal cross-talk involves an elaborate and coordinated network
of communication via timely released embryonic and maternal-
derived signals and well-targeted actions. Optimal receptivity of
the human endometrium to the implantation of a competent
blastocyst occurs during a limited period of time within the
menstrual cycle called ‘‘implantation window’’, which is generally
believed to span d6–10 following luteinizing hormone (LH) peak in
the normal menstrual cycle [1,2]. Numerous studies showed major
and specific changes arising within this specific time interval,
which encompass adhesion, invasion, survival, growth, differenti-
ation and immune-modulating factors that shape up endometrial
receptivity. The dynamics of this transition from a non-receptive
to a receptive endometrium are poorly understood, but the correct
spatio-temporal synthesis and balance of various factors is thought
to play an important role in human uterine preparation for
implantation [3,4,5].
Indeed, under the influence of a developing embryo, endocrine
factors, particularly ovarian hormones, play a critical role in the
regulation of the molecular changes that occur. Embryonic human
chorionic gonadotropin (hCG) maintains for instance the produc-
tion of progesterone by the corpus luteum, which is critical to
sustain early pregnancy. However, direct interactions at the fetal-
maternal interface and appropriate coordination between embry-
onic and maternal signals at the implantation site are essential for
providing the synergistic environment needed for the establish-
ment of pregnancy [6,7].
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hCG is a major embryonic signal playing a key role in the
initiation and maintenance of pregnancy [8]. It is transcribed as
early as the 2-cell embryo stage [9] and is produced abundantly by
the trophectodermal cells of the pre-implantation blastocyst [10].
Following implantation, hCG is produced by syncytiotrophoblast
of the developing conceptus [11]. Recent evidence suggests that
hCG is also produced in glandular and luminal epithelium of
human endometrium, primarily during the secretory phase
[12,13]. hCG production by embryonic cells may directly regulate
the expression of endometrial factors and extend the period during
which the endometrium is receptive [2,14].
hCG acts on the intrauterine environment via the luteinizing
hormone (LH)/hCG receptor (hLHCGR), which was detected in
various cell types including human uterus and decidua, placenta
and fetal membranes [15,16]. Synthesized early by the tropho-
blast, hCG may therefore have a wide spectrum of cell targets and
biological actions that influence endometrial receptivity and
embryo implantation. It promotes human endometrial stromal
cell (ESC) decidualization [17] via functional differentiation
resulting in an up-regulation of cyclooxygenase 2 (COX2) gene
expression and increased production of prostaglandin (PG)E2 [18],
possesses both direct and indirect angiogenic properties [19],
induces tissue specific human uterine natural killer (uNK) cell
proliferation [20] and regulates embryonic autocrine and maternal
paracrine factors involved in embryo attachment, endometrial
remodeling, antioxidant defense and immune mechanisms around
the implanting blastocyst [2,21,22].
Several studies provide strong evidence that interleukin (IL1)B
may play a pivotal role at the embryo-maternal interface and
represents one of the earliest signals [23,24,25,26,27]. IL1 is
synthesized by the human embryo during its initial stages, and the
concentration of this cytokine has been positively correlated with
successful implantation after in vitro fertilization and transfer to the
uterine cavity [28,29]. A key regulator of the inflammatory
response, IL1 is currently recognized as a multifunctional cytokine
with a wide spectrum of effects on numerous cell types (eg nervous
system cells, immune cells, connective tissue cells, endometrial
cells, hepatocyte, fibroblast and endothelial cells) [30,31]. IL1 acts
on human endometrial cells to induce the secretion of leukemia
inhibitory factor (LIF) and PGE2 [32,33], which play an important
role in the implantation process [34], up-regulates the expression
of integrin b3, a marker of uterine receptivity, in human
endometrial epithelial cells [35] and stimulates the migration of
human first-trimester villous cytotrophoblast cells via endometri-
um-derived factors [36]. Purified human cytotrophoblasts in
culture release IL1B in the manner that parallels their invasive
potential [37]. IL1B stimulates the release of human placental
metalloproteinase (MMP)9 [37], proMMP3 expression in baboon
stromal cells [38] and hCG by first trimester human trophoblastic
cells [39].
The IL1 system is composed of two receptors (IL1R1 and
IL1R2), one accessory protein (IL1 RAP) also called IL1R3, one
receptor antagonist (IL1RN) and two agonists (IL1A and IL1B),
which both trigger cell activation via the functional signaling
IL1R1 [40]. IL1R2 rather acts as a negative regulator of IL1
action. Either the membrane-bound (mb) or the soluble (s) form of
IL1R2, which is released by proteolysis from the cell surface, acts
by capturing IL1, thereby inhibiting IL1-mediated cell activation
[41].
Our previous studies pointed to new mechanisms by which the
embryo may fine-tune the receptivity of the maternal endometri-
um, and revealed the ability of hCG to interact with different
human endometrial cell types and modulate cell receptivity to IL1.
Actually, hCG appeared to down-regulate the expression of the
inhibitory IL1R2 in endometrial epithelial cells without affecting
that of the activating IL1R1 [42]. Comparable effects were
observed in ESCs during the implantation window with,
interestingly, a concomitant up-regulation of IL1R1, a down-
regulation of IL1RN, an increased angiogenic activity and a
higher secretion of monocyte chemotactic protein1 (MCP1) [23].
First identified as a specific factor for macrophage recruitment and
activation, MCP1 was later found to be endowed with various
immune modulating, proangiogenic and growth-promoting prop-
erties [43,44]. The aim of the present work was to gain a broader
understanding of the global impact of hCG on the modulation of
Table 1. List of PCR primers.
Gene Primer Tm6C
CCL2 F-CTCTGCCGCCCTTCTGT 60
R-CTTCTTTGGGACACTTGCTG
CCL5 F-CTCGCTGTCATCCTCA 56
R-CACTTGCCACTGGTGTA
CCL7 F-GCCTCTGCAGCACTTCTGTG 60
R-CACTTCTGTGTGGGGTCAGC
CCL8 F-CTTCAAGACCAAACGG 52
R-GAATCCCTGACCCAT
GAPDH F- CAGGGCTGCTTTTAACTCTGG 60
R-TGGGTGGAATCATATTGGAACA
IL18R1 F-CTGGAGGAGCTGTTGT 60
R-GATTAGTCTTCGGCTTT
IL1A F-AAGACAGTTCCTCCAT 52
R-TTGCTACTACCACCAT
IL1B F-ACAGTGGCAATGAGGATG 58
R-TGTAGTGGTGGTCGGAGA
IL1RL1 F-CTGAGGACGCAGGTGA 54
R-CTCCGATTACTGGAAACA
IL18 F-GCCAGCCTAGAGGTATG 60
R-GTTATCAGGAGGATTCATTT
IL33 F-CAGGTGACGGTGTTG 56
R-TGTAGGACTCAGGGTTA
IL6 F-GGAGACTTGCCTGGTGAA 60
R-GCATTTGTGGTTGGGTCA
KRT19 F-CGACAATGCCCGTCTG 58
R-GCCTGTTCCGTCTCAAA
MMP10 F-CAAGAGGCATCCATAC 54
R-AACCTTAGGCTCAACT
MMP9 F-TTGACAGCGACAAGAAGTGG 54
R-CCCTCAGTGAAGCGGTACAT
PTGS2 F-TCCCTTGGGTGTCAAAGGTAA 60
R-AAAACTGATGCGTGAAGTGCTG
TIMP3 F-CTCCGACATCGTGATC 54
R-TCCTTTACCAGCTTCTT
VCAM1 F-TGAAGGATGCGGGAGT 58
R-GCAGGTATTATTAAGGAGG
VEGFC F-GCCAGCAACACTACCA 58
R-TTGAGTCATCTCCAGCAT
doi:10.1371/journal.pone.0064829.t001
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human endometrial cell responsiveness to IL1 and the acquisition
of growth-promoting phenotype capable of sustaining active
embryonic implantation and growth. Using micro-array analysis
of hCG, IL1 and hCG/IL1-treated ESCs from the implantation
window, our data identified several significantly regulated genes
targeted by hCG/IL1 synergy and implicated in angiogenesis,
proliferation, tissue remodeling, cell signaling and immune
modulation, which is relevant to early embryo implantation
process, and a wide spectrum of targets encompassing IL1 family
members.
Materials and Methods
Subjects and tissue handling
Endometrial tissue specimens were obtained during the
implantation window (days 19 to 24) from normal fertile women
with a regular menstrual cycle, who were undergoing laparoscopy
for tubal ligation and had not received hormonal or anti-
inflammatory therapy for at least 3 months prior to surgery (mean
age 6 SD, 35.664.9 yr.; n=7). Menstrual cycle day was
determined according to the histological criteria of Noyes et al
[45]. A written informed consent was obtained from participants
under a study protocol approved by the Ethics Committee on
Human Research of Laval University, Quebec, Canada. Collec-
tion of endometrial tissue biopsies was performed using a Pipelle
(Unimar Inc., Prodimed, Neuilly-En-Thelle, France). Tissue
samples were kept at 4uC in sterile Hank’s balanced salt solution
(HBSS) containing 100 U/mL penicillin, 100 mg/mL streptomy-
cin and 0.25 mg/mL amphotericin B (Invitrogen Life Technolo-
gies, Burlington, ON, Canada) and immediately transported to the
laboratory.
Cell culture and treatment
ESCs were isolated and characterized according to our
previously described procedure [46]. Concisely, tissue was minced
into small pieces, dissociated with collagenase before ESCs were
separated by differential sedimentation and adhesion. The purity
of primary ESC cultures was tested morphologically by light
microscopy and immunocytochemically on parallel cultures, as
previously described. Cultures were free of CD452positive
leukocytes and contamination by factor VIII-positive endothelial
cells was generally less than 1%. ESCs were cultured at 37uC in
DMEM:F12 (1:1) supplemented with 10% fetal bovine serum
(FBS), insulin, transferrin, and a mix of antibiotics–antimycotics.
Preconfluent cells were washed with HBSS, incubated overnight
with charcoal-treated FBS-supplemented medium, washed with
phenol red-free DMEM:F12 (1:1) and cultured with phenol red-
Figure 1. Analysis of genes significantly modulated by each treatment. A) Headmap of probe sets corresponding to genes significantly
modulated (P,0.05) in each group. Increased signal intensities are displayed in red, whereas lower signal intensities are shown in blue. Cluster
distances were evaluated by Spearman correlation on average linkage (Partek Genomics Suite). B) PCA scatter plot of all samples was generated to
assess the variability of micro-array data. Each sphere represents a whole chip data. As shown in the legend, samples are colored by treatment and
grouped by an ellipsoid that considers two standard deviations from the center of each group. C) Venn diagram of the respective gene lists showing
the overlap of action between hCG/MM, MM/IL1B and hCG/IL1B. Data were obtained with ESC cultures issued from 3 different subjects.
doi:10.1371/journal.pone.0064829.g001
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and FBS-free medium containing hCG (100 ng/mL, recombinant
protein expressed in a mouse cell line, 10,000 IU/mg; Sigma-
Aldrich Co., St. Louis, MO) for 24 h. Cells were then incubated
with a fresh phenol red- and FBS-free medium containing IL1B
(0.1 ng/mL, R&D Systems, Minneapolis, MN) for additional
24 h. hCG and IL1B concentrations were determined based on
our previous studies with human ESCs where different doses were
used (Bourdiec A et al, Biol Reprod, 2012). hCG and IL1B
concentrations are within the range of the molecules’ physiological
concentrations [28,47].
RNA preparation and micro-array analysis
Total RNA of ESC cultures issued from 3 different women was
extracted with Trizol according to the manufacturer’s directions
(Invitrogen). Then they were washed using the micro RNeasy Kit
(Quiagen). Total RNA quantity was measured with Nanodrop
ND-1000 spectrophotometer (Nanodrop Technologies Inc.,
DE,USA) and RNA integrity was assessed by capillary electro-
phoresis using the Bioanalyzer 2100 (Agilent Technologies,
Mississauga, Ontario, Canada). DNA micro-array analyses were
carried out with Affymetrix Human Gene 1.0 ST at the Gene
Expression Platform of the Research Centre of Laval University
Hospital Centre, Quebec, Canada. The array interrogates 28,869
well-annotated genes with 764,885 distinct probes. The design of
the Human Gene 1.0 ST Array was based on the March 2006
human genome sequence assembly (UCSC Hg18, NCBI build 36)
with comprehensive coverage of RefSeq, Ensembl and putative
complete CDS GenBank transcripts. Chips were processed
according to the Affymetrix standard protocol. Briefly, total
RNA (150 ng per sample) was labeled using the Ambion WT
Expression kit and Affymetrix GeneChipHWT Terminal Labeling
kit, and hybridized to the arrays as described by the manufacturer
(Affymetrix, Santa Clara, CA). The cDNA hybridization cocktail
was incubated overnight at 45uC while rotating in a hybridization
oven. After 1761 h of hybridization, the cocktail was removed
and the arrays were washed and stained in an Affymetrix
GeneChip fluidics station 450, according to Affymetrix protocol
(http://media.affymetrix.com/support/downloads/manuals/
wt_sensetarget_label_manual.pdf). The arrays were scanned using
the Affymetrix GCS 3000 7G and the Affymetrix Expression
Console Software (Affymetrix, Santa Clara, CA), to produce the
intensity files.
Data analysis, background subtraction, and intensity normali-
zation were performed using Robust Multiarray Analysis [48].
Differentially expressed genes and false discovery rate were
estimated from t test (P,0.05) and corrected using Bayes approach
[49]. Data analysis, hierarchical clustering, and ontology was
performed using the OneChanelGUI to extend affylmGUI
graphical interface capabilities [50] and Partek Genomics Suite,
version 6.5 (Partek Inc., St. Louis, MO) with analysis of variance
analysis.
Quantitative real time PCR
RNA was extracted using the standard TrizolH protocol
(Invitrogen) as previously reported _ENREF_36[51]. Quantitative
real time (qRT)-PCR was performed on the same 3 cultures used
for microarray analysis and 4 more different cultures. An ABI
7000 Thermal Cycler (Applied Biosystems, Foster City, CA) was
used. Each standard PCR reaction contained 2 mL reverse
transcriptase (RT) product, 0.5 mL of primer (final concentration,
0.1 mM), 12.5 mL of SYBR Green PCR Master Mix (Invitrogen)
consisting of Taq DNA polymerase reaction buffer, Taq DNA
polymerase, SYBR green I, deoxynucleotide triphosphate mix and
MgCl2. The reaction melting temperature (Tm) and the list of
primers are reported in the Table 1. Primers were designed with
Primer Premier 5 software to cross intron-exon boundaries. All
Figure 2. Enrichment score of biological processes. A) GO analysis was used to identify the main biological processes targeted by gene lists
and significantly modulated by each treatment. Each functional group was assigned with a GO enrichment score that was calculated using a chi2 test.
B) A forest plot using the same gene list was also generated to show the percentage of differentially expressed genes that were up-regulated (red) or
down-regulated (blue) for each biological process. Light color: gene populations with a fold change ranging from 1.5 to 2. Dark color: gene
populations with a fold change above 2. Data were obtained with ESC cultures issued from 3 different subjects.
doi:10.1371/journal.pone.0064829.g002
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Table 2. Genes up-regulated after in vitro treatment of human endometrium stromal cells.
Gene
p-value
hCG/IL1
FC
hCG/IL1
p-value
MM/IL1
FC
MM/IL1
p-value
hCG/MM
FC
hCG/MM IPA Pf.
IPA
Im.
IPA
Rm.
IPA
CS.
IPA
Ap.
IPA
Ag.
CXCL6 0.00001 35.52 0.00002 21.51 X X
IL6a´ 0.00088 15.06 0.00147 12.16 X X X X X X
CXCL1 0.00067 13.94 0.00090 12.35 X X X X
TNFAIP3 0.00005 13.72 0.00027 8.03 X X X
IL1Ba´ 0.00076 13.13 0.00020 23.61 X X X X X
CYP7B1 0.00000 12.96 0.00001 5.09 0.02288 1.60 X X
TNFAIP6 0.00013 11.79 0.00448 4.08 X
PTGS2a´ 0.00203 10.48 0.00368 8.33 X X X X X
CCL5a´aˆ 0.01045 9.57 0.03962 5.30 X X X X
IL8 0.00318 9.27 0.00227 10.59 X X X X
C3 0.00337 8.42 0.01599 4.83 X X X X
VCAM1a´ 0.00099 8.08 X X X
ITGB8 0.00002 8.07 0.00079 3.39 X X
CXCL2 0.00077 7.25 0.00343 4.69 X X X
TNFAIP2 0.00004 7.10
CCL2a´aˆ 0.00249 6.74 0.01108 4.25 X X X X
CTSS 0.00014 6.68 0.00064 4.57 X X X
IRAK3 0.00001 6.56 0.00023 3.58 X X X
CFB 0.00235 6.14 X X
EPSTI1 0.00639 5.55
IL24 0.00217 5.26 0.00063 7.59 X X X X
IL13RA2 0.01786 5.17 0.03330 4.14 X
MMP12 0.01798 4.49 0.01483 4.79
NFKBIZ 0.00003 4.14 0.00005 3.84 X
CX3CL1 0.02049 3.95 X X X X
IL7R 0.00167 3.92 0.00162 3.95 X X X X X
FGF7 0.00367 3.87 0.02245 2.57 X X X X
GNA15 0.00250 3.85 X
CXCL3 0.00228 3.81 X X X
CSF1 0.00613 3.60 X X X X X
CCL8a´ 0.00031 3.47 X X
ZC3H12A 0.00003 3.23 0.00010 2.76
ICAM1 0.00001 3.13 0.00002 2.94 X X X X X
IL32 0.00011 3.07 0.00285 1.97 X X X X
ANK2 0.00002 3.05 0.00215 1.73
CXCL5 0.01034 3.02 0.01015 3.04 X X
IL15RA 0.00093 2.94 X X X X
IL1Aa´ 0.00012 2.88 0.00001 4.43 X X X X X
PTGES 0.00004 2.84 X X X X
ITGA8 0.01123 2.76
IRAK2 0.01232 2.67 0.00250 3.75 X X
NFKBIA 0.00003 2.60 0.00007 2.37 X X X X
WNT2 0.00299 2.54 0.00760 2.20 X X
LIF 0.00019 2.37 0.00078 2.01 X X X X X
CYP1B1 0.01872 2.35 X X X
BAMBI 0.04533 2.28 X
IL1RL1a´ 0.01807 2.05 X X X X
FGF2 0.00006 1.93 0.00006 1.93 X X X
HLA-DOB 0.00425 1.89
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Table 2. Cont.
Gene
p-value
hCG/IL1
FC
hCG/IL1
p-value
MM/IL1
FC
MM/IL1
p-value
hCG/MM
FC
hCG/MM IPA Pf.
IPA
Im.
IPA
Rm.
IPA
CS.
IPA
Ap.
IPA
Ag.
C1R 0.00242 1.83
CCL7a´ 0.03055 1.80 X X
Gene
p-value
hCG/IL1
FC
hCG/IL1
p-value
MM/IL1
FC
MM/IL1
p-value
hCG/MM
FC
hCG/MM
IPA
Pf.
IPA
Im.
IPA
Rm.
IPA
CS.
IPA
Ap.
IPA
Ag.
C1S 0.00019 1.79 0.00136 1.54
HLA-F 0.00278 1.71
IL20 0.00004 1.69 X X
FOXP1 0.00162 1.66 X X X
IL18R1a´ 0.00483 1.65 X X
IFNGR1 0.01156 1.65 X X X
C2 0.02976 1.65
SPAG1 0.01701 1.64
IL7 0.00011 1.63 X X X X X
TNFRSF1B 0.00134 1.62 X X X X X
IL17RB 0.01191 1.62 X
HLA-E 0.00189 1.61 X
DUSP1 0.01584 1.57 X X X X
NFKB1 0.00005 1.56 X X X X X
PDGFC 0.00670 1.52 X X
EGFR 0.00112 1.51 X X X
CLDN12 0.00231 1.50 ?
INHBA 0.03972 2.82 X X X X
CLDN1 0.00226 2.42 X
SERPINB3 0.01389 2.09 X X X
CYP19A1 0.04113 2.05 X
VEGFCa´aˆ 0.03365 2.05 X X X
MMP9a´aˆ 0.00034 1.93 X X X X
MMP3 0.02941 1.81 X X
IL4R 0.00190 1.77 X X X X X
SAT1 0.01189 1.68 X X
EPHA6 0.01086 1.67
TRAF3IP2 0.00848 1.63 X X
NFKB2 0.00022 1.62 X X X X
MMP13 0.01643 1.62 X X
ADAM12 0.02572 1.60 X X
CASP3 0.00748 1.59 X X X X
ALDH1A1 0.00743 4.10 X X
CD34 0.00212 2.14 X
FAT4 0.00889 2.14
CXCL12 0.04752 2.06 X X X X X
ANGPTL2 0.01814 1.96
CLDN11 0.01104 1.96 X X
SEPP1 0.02775 1.93 X
TMOD1 0.00298 1.92 X
C1RL 0.02441 1.67
CADM1 0.01684 1.66 X X X
C4A 0.04847 1.66 X X
CRYAB 0.04510 1.62 X X
CNN1 0.03209 1.60 X
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samples were tested in duplicate and for each reaction negative
controls without RNA and without reverse transcriptase were
included.
Enzyme-Linked Immunosorbent Assay (ELISA)
CCL2 and CCL5 concentrations in the culture medium were
measured using previously reported sandwich ELISAs [52,53].
VEGFC, TIMP3, MMP9 and prolactin were measured using
DuoSet kit (DuoSet, R&D Systems, Minneapolis, MN), according
to the manufacturer’s instructions.
Statistical analysis
qRT-PCR and ELISA data followed a parametric distribution
and were expressed as means 6 SEM. Statistical analyses were
performed with GraphPad Software Prism 4.0 (GraphPad
Software, Inc., San Diego, CA, USA). The significance of
statistical differences was determined using one way analysis of
variance (ANOVA) followed by the Bonferroni test post hoc, for
multiple comparisons, and the Student’s t-test for the comparison
of two groups.
Results
Gene expression profile for all experiments
Total RNA was isolated from primary human ESCs treated
with hCG (100 ng/mL) for 24 h before being stimulated or not
with IL1B (0.1 ng/mL) for additional 24 h. RNA from all treated
groups was compared by micro-array with the corresponding non-
treated control using Affymetrix GeneChip Human Genome.
Using Significance Analysis of Micro-arrays (SAM), all genes
significantly regulated between treated versus the non-treated
group were selected [fold change (FC) 1.5 and a false discovery
rate (FDR) ,5%]. The unsupervised hierarchical clustering
analysis of the array data showed specific molecular signatures
of the global gene expression for each group and a noticeable
discrimination between IL1B-treated and IL1B-untreated cells
with and without hCG pre-treatment (Figure 1A). Three
dimensional Principal Component Analysis (PCA) further showed
different patterns of gene expression and a clear segregation
between the four groups included in this study [MM/MM (control
minimal medium), hCG/MM, MM/IL1B and hCG/IL1B
treatments). Also, samples from the same group were very tightly
clustered together, which corroborates the robustness of the
Affymetrix micro-arrays (Figure 1B).
Gene expression profile in ESCs is under embryonic
stimuli
The different gene lists identified using SAM analysis (FC 1.5
and an FDR ,5%) of treatment versus control groups were then
intersected to determine their overlap. The results showed that 9
significantly regulated genes were common to all treatments, and
97, 211 and 497 genes were independently regulated by hCG,
IL1B and hCG/IL1, respectively (Figure 1C), thereby suggesting
highly specific expression profiles.
Genes ontology (GO) of biological processes
Gene ontology (GO) annotations were then used to explore the
specific functional properties of the molecular signatures. A
functional enrichment analysis was performed using Partek
software (Figure 2). Only significant biological functions were
reported. The molecular signature of hCG/MM-treated group
was enriched in genes associated with the regulation of cell
response to stimulus, cellular and metabolic processes and cellular
component organization. Analysis of the IL1B-treated group
identified several enriched GO categories that were linked to
multi-organism process, immune system process, death, biological
adhesion, locomotion, biological regulation, developmental pro-
cess and response to stimulus, with a marked increase in the latter
process. In hCG/IL1 treated group, most enriched GO categories
were similar to those found in the IL1B-treated group, but the
enrichment scores appeared to be different. The most perceptible
increase over hCG and IL1B/hCG was related to cellular,
biological regulation and immune system processes, whereas other
processes such as biological adhesion and response to stimulus
seemed to be lessened to some extent. As observed in the forest
plot shown in Figure 2B, IL1B increased the percentage of
differentially up- and down- regulated gene populations with a fold
change above 2 in each of these biological processes, while co-
exposure to hCG led globally to a more moderated regulation.
These observations are noteworthy considering the possible
involvement of these critical biological processes in the embryo-
maternal crosstalk and the establishment of pregnancy.
Identification of differentially expressed genes implicated
in early embryo implantation
Tables 2–5 summarize significantly up- and down-regulated
genes in ESCs in response to hCG, IL1 and hCG/IL1 compared
to untreated control cells. Genes were ranked according to the
average of the fold change. To validate changes in the level of
RNA transcripts, we have selected some genes found to be
significantly regulated upon hCG, IL1B or hCG/IL1B treatment
by micro-array and known for being involved in proliferation,
immune modulation, tissue remodeling, cell signaling, apoptosis
Table 2. Cont.
Gene
p-value
hCG/IL1
FC
hCG/IL1
p-value
MM/IL1
FC
MM/IL1
p-value
hCG/MM
FC
hCG/MM
IPA
Pf.
IPA
Im.
IPA
Rm.
IPA
CS.
IPA
Ap.
IPA
Ag.
SLC2A12 0.00483 1.58
HSD17B6 0.02452 1.55
SMAD9 0.02996 1.54
ITPR1 0.00157 1.53 X X X X
Pf, proliferation; Im, immune functions; Rm, tissue remodeling; CS, cell signaling; Ap, apoptosis; Ag, angiogenesis
a´/aˆReal-time PCR/ELISA validation performed
Genes up-regulated after in vitro treatment of human endometrium stromal cells
doi:10.1371/journal.pone.0064829.t002
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Table 3. Name of up-regulated genes.
RefSeq Gene symbol Genes name
NM_002993 CXCL6 chemokine (C-X-C motif) ligand 6
NM_000600 IL6 interleukin 6 (interferon, beta 2)
NM_001511 CXCL1 chemokine (C-X-C motif) ligand 1
NM_006290 TNFAIP3 tumor necrosis factor, alpha-induced protein 3
NM_000576 IL1B interleukin 1, beta
NM_004820 CYP7B1 cytochrome P450, family 7, subfamily B, polypeptide 1
NM_007115 TNFAIP6 tumor necrosis factor, alpha-induced protein 6
NM_000963 PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)
NM_002985 CCL5 chemokine (C-C motif) ligand 5
NM_000584 IL8 interleukin 8
NM_000064 C3 complement component 3
NM_001078 VCAM1 vascular cell adhesion molecule 1
NM_002214 ITGB8 integrin, beta 8
NM_002089 CXCL2 chemokine (C-X-C motif) ligand 2
NM_006291 TNFAIP2 tumor necrosis factor, alpha-induced protein 2
NM_002982 CCL2 chemokine (C-C motif) ligand 2
NM_004079 CTSS cathepsin S
NM_007199 IRAK3 interleukin-1 receptor-associated kinase 3
NM_001710 CFB complement factor B
NM_001002264 EPSTI1 epithelial stromal interaction 1 (breast)
NM_006850 IL24 interleukin 24
NM_000640 IL13RA2 interleukin 13 receptor, alpha 2
NM_002426 MMP12 matrix metallopeptidase 12 (macrophage elastase)
NM_031419 NFKBIZ nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta
NM_002996 CX3CL1 chemokine (C-X3-C motif) ligand 1
NM_002185 IL7R interleukin 7 receptor
NM_002009 FGF7 fibroblast growth factor 7
NM_002068 GNA15 guanine nucleotide binding protein (G protein), alpha 15
NM_002090 CXCL3 chemokine (C-X-C motif) ligand 3
NM_000757 CSF1 colony stimulating factor 1 (macrophage)
NM_005623 CCL8 chemokine (C-C motif) ligand 8
NM_025079 ZC3H12A zinc finger CCCH-type containing 12A
NM_000201 ICAM1 intercellular adhesion molecule 1
NM_001012631 IL32 interleukin 32
NM_001148 ANK2 ankyrin 2, neuronal
NM_002994 CXCL5 chemokine (C-X-C motif) ligand 5
NM_002189 IL15RA interleukin 15 receptor, alpha
NM_000575 IL1A interleukin 1, alpha
NM_004878 PTGES prostaglandin E synthase
NM_003638 ITGA8 integrin, alpha 8
NM_001570 IRAK2 interleukin-1 receptor-associated kinase 2
NM_020529 NFKBIA nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha
NM_003391 WNT2 wingless-type MMTV integration site family member 2
NM_002309 LIF leukemia inhibitory factor
NM_000104 CYP1B1 cytochrome P450, family 1, subfamily B, polypeptide 1
NM_012342 BAMBI BMP and activin membrane-bound inhibitor homolog
NM_016232 IL1RL1 interleukin 1 receptor-like 1
NM_002006 FGF2 fibroblast growth factor 2 (basic)
NM_002120 HLA-DOB major histocompatibility complex, class II, DO beta
NM_001733 C1R complement component 1, r subcomponent
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Table 3. Cont.
RefSeq Gene symbol Genes name
NM_006273 CCL7 chemokine (C-C motif) ligand 7
NM_201442 C1S complement component 1, s subcomponent
NM_001098479 HLA-F major histocompatibility complex, class I, F
NM_018724 IL20 interleukin 20
NM_032682 FOXP1 forkhead box P1
NM_003855 IL18R1 interleukin 18 receptor 1
NM_000416 IFNGR1 interferon gamma receptor 1
NM_000063 C2 complement component 2
NM_003114 SPAG1 sperm associated antigen 1
NM_000880 IL7 interleukin 7
NM_001066 TNFRSF1B tumor necrosis factor receptor superfamily, member 1B
NM_018725 IL17RB interleukin 17 receptor B
RefSeq Gene symbol Genes name
NM_005516 HLA-E major histocompatibility complex, class I, E
NM_004417 DUSP1 dual specificity phosphatase 1
NM_003998 NFKB1 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1
NM_016205 PDGFC platelet derived growth factor C
NM_005228 EGFR epidermal growth factor receptor
NM_001185072 CLDN12 claudin 12
NM_002192 INHBA inhibin, beta A
NM_021101 CLDN1 claudin 1
NM_006919 SERPINB3 serpin peptidase inhibitor, clade B (ovalbumin), member 3
NM_031226 CYP19A1 cytochrome P450, family 19, subfamily A, polypeptide 1
NM_005429 VEGFC vascular endothelial growth factor C
NM_004994 MMP9 matrix metallopeptidase 9
NM_002422 MMP3 matrix metallopeptidase 3 (stromelysin 1, progelatinase)
NM_000418 IL4R interleukin 4 receptor
NR_027783 SAT1 spermidine/spermine N1-acetyltransferase 1
NM_001080448 EPHA6 EPH receptor A6
NR_028338 TRAF3IP2 TRAF3 interacting protein 2
NM_002502 NFKB2 nuclear factor of kappa light polypeptide gene enhancer in B-cells 2
NM_002427 MMP13 matrix metallopeptidase 13 (collagenase 3)
NM_003474 ADAM12 ADAM metallopeptidase domain 12
NM_004346 CASP3 caspase 3, apoptosis-related cysteine peptidase
NM_000689 ALDH1A1 aldehyde dehydrogenase 1 family, member A1
NM_001773 CD34 CD34 molecule
NM_024582 FAT4 FAT tumor suppressor homolog 4 (Drosophila)
NM_000609 CXCL12 chemokine (C-X-C motif) ligand 12
NM_012098 ANGPTL2 angiopoietin-like 2
NM_005602 CLDN11 claudin 11
NM_005410 SEPP1 selenoprotein P, plasma, 1
NM_003275 TMOD1 tropomodulin 1
NM_016546 C1RL complement component 1, r subcomponent-like
NM_014333 CADM1 cell adhesion molecule 1
NM_007293 C4A complement component 4A (Rodgers blood group)
NM_001885 CRYAB crystallin, alpha B
NM_001299 CNN1 calponin 1, basic, smooth muscle
NM_145176 SLC2A12 solute carrier family 2 (facilitated glucose transporter)
NM_003725 HSD17B6 hydroxysteroid (17-beta) dehydrogenase 6 homolog (mouse)
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and angiogenesis, which are crucial for early embryo implantation.
qRT-PCR was performed for the MCPs [chemokine C-C motif
ligand (CCL)2 or MCP1, CCL8 or MCP2 and CCL7 or MCP3],
vascular cell adhesion molecule 1(VCAM1), IL6, CCL5 or
regulated and normal T cell expressed and secreted (RANTES),
PG synthase (PTGS)2 or COX2, vascular endothelial growth
factor C (VEGFC), MMP9, tissue inhibitor of metalloproteinase 3
(TIMP3) and keratin 19 (KRT19), and for IL1 family members
IL1R-like 1 (IL1RL1) or IL33R, IL18R1, their respective ligands
(IL33 and IL18) and both IL1 isoforms A and B.
Our previous studies showed that hCG acts on ESCs, in synergy
with IL1B, to stimulate the expression of CCL2 (MCP1), a
monocyte/macrophage chemotactic factor with potent angiogenic
properties, via the creation of an imbalance between IL1R1 and
IL1R2 expression [23]. Micro-array analysis and qRT-PCR
validation indicated that not only CCL2, but CCL8 (MCP2)
and CCL7 (MCP3) were significantly upregulated by hCG/IL1 as
well (P,0.001, P,0.05 and P,0.001, respectively). Furthermore,
a significant increase of CCL2, CCL8 and CCL7 mRNA
transcripts in cells exposed to hCG/IL1B compared to hCG was
noted (P,0.001, P,0.05 and P,0.001, respectively), whereas
only CCL2 and CCL7 mRNA transcripts were significantly
increased in cells treated with hCG/IL1B compared to IL1B
(P,0.05) (Figure 3 A, B and C).
Many other cytokines and growth factors known for being
involved in the regulation of immune responses, adhesion, cell
proliferation and angiogenesis were also found to be targeted by
hCG and IL1B synergistic action. Vascular cell adhesion protein
1, which mediates leukocyte adhesion to vascular endothelium,
was significantly up-regulated by hCG/IL1B compared to the
control minimal medium (MM) (P,0.01), but neither hCG nor
IL1B had a statistically significant stimulatory effect (Figure 4A).
IL6 and CCL5 mRNA levels were significantly increased by
hCG/IL1B compared to MM (P,0.05 and P,0.01, respectively)
or to hCG (P,0.05 and P,0.01, respectively). CCL5 levels were
also significantly increased in cells treated with hCG/IL1B
compared to IL1B (P,0.05) (Figure 4B, C).
PTGS2, a major rate-limiting enzyme involved in PG synthesis,
and VEGFC, an isoform of a potent angiogenic factor, also
showed an increased mRNA expression in cells treated with hCG/
IL1B compared to cells incubated with MM (P,0.001 and
P,0.01, respectively) or with hCG alone (P,0.001 and P,0.01,
respectively). IL1B stimulated PTGS2 and VEGFC mRNA
synthesis as well (P,0.05), but cell exposure to hCG significantly
stimulated in the IL1B-induced PTGS2 expression (P,0.05)
(Figure 4D, E).
Also found to be regulated were some molecules shown to
participate in endometrial tissue remodeling such as MMP9,
TIMP3 and KRT19 (Figure4F, G, H). MMP9 was significantly
up-regulated by IL1B and hCG/IL1B (P,0.01 and P,0.05,
respectively). By itself, hCG had no statistically significant effect on
MMP9 expression, but it moderated the IL1B-induced effect.
TIMP3, a natural tissue inhibitor of MMPs, was down-regulated
by IL1B either in the presence or the absence of hCG (P,0.05).
Cytokeratin 19 (KRT19), an intermediate filament protein
associated with embryonic placenta development [54], was found
to be significantly inhibited by IL1B (P,0.05) and more by IL1B
combined with hCG (P,0.01).
hCG modulates IL1B effects on the expression of IL1
family members in ESCs
Our previous studies showed that hCG down-regulates the
IL1B-induced increase of IL1R2 and IL1RN in ESCs and
amplifies the IL1B-induced increase of IL1R1 [23]. Our current
micro-array analysis further revealed that hCG/IL1B interaction
may affect ESC responsiveness to other components of IL1 family
including IL1 isoforms A and B as well as IL1RL1 and IL18R1
(Tables 2 and 4). To validate these findings, qRT-PCR analysis
was performed. Our results showed that IL1B induced both ILA
and IL1B in ESCs (P,0.01 and P,0.001, respectively), but hCG
moderated that endogenous IL1B-mediated expression (Figure5 A,
D). However, both IL1 isoforms remained significantly up-
regulated compared to the control medium (P,0.05) despite the
down-regulatory effect of hCG. Furthermore, the micro-array
data predicted a synergistic interaction between hCG and IL1B,
resulting in the induction of IL18R1 and IL1R1L expression
(Figure 5 B, E). This was confirmed by qRT-PCR analysis, which
showed a significant up-regulation of these two receptors as
compared to control (P,0.05 and P,0.001, respectively) and to
hCG (P,0.05 and P,0,001, respectively). However, despite a
noticeable increase of IL1RL1 and IL1R18 in hCG/IL1B-treated
compared to IL1B-treated cells, this increase was statistically
significant only for IL18R1 (P,0.01), but did not reach statistical
significance for IL1RL1 with these small groups.
Because IL18R1 and IL1RL1 were targeted by hCG/IL1B, we
have then investigated their ligands (IL18, IL33) by qRT-PCR.
Our data showed that like IL1A and IL1B, both IL33 and IL18
were up-regulated in cells treated with IL1B (P,0.01 and P,0.05,
respectively), but they were down-regulated in cells treated with
hCG and IL1B compared to IL1B alone (P,0.01) (Figure 5 C, F).
Validation of selected soluble proteins
To confirm the gene expression changes at the protein level, we
have selected some genes found to be significantly regulated upon
hCG, IL1B or hCG/IL1B treatment and known for being
involved in immune modulation, tissue remodeling and angiogen-
esis. Results indicated that CCL2 was significantly upregulated by
hCG/IL1B (P,0.001), which corroborates the microarray data
(Figure 6A). CCL5 secretion was upregulated either by IL1B or
hCG/IL1B (P,0.05), but hCG/IL1B synergism was not percep-
tible at the protein level (Figure 6 B). hCG/IL1B treatment further
appeared to upregulate VEGFC (P,0.001) and downregulate
TIMP3 secretion (P,0.001) (Figure 6 C, D). MMP9 was
significantly up-regulated by IL1B (P,0.05), but hCG/IL1 did
not show a statistically significant stimulatory effect (Figure 6E).
Table 3. Cont.
RefSeq Gene symbol Genes name
NM_001127217 SMAD9 SMAD family member 9
NM_001168272 ITPR1 inositol 1,4,5-triphosphate receptor, type 1
Name of up-regulated genes.
doi:10.1371/journal.pone.0064829.t003
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Table 4. Genes down-regulated after in vitro treatment of human endometrium stromal cells.
Gene
p-value
hCG/IL1
FC
hCG/IL1
p-value
MM/IL1
FC
MM/IL1
p-value
hCG/MM
FC
hCG/MM
IPA
Pf.
IPA
Im.
IPA
Rm.
IPA
CS.
IPA
Ap.
IPA
Ag.
ETV1 0.02017 25.26
HSD17B2 0.03976 25.06
LOXL4 0.00528 24.74 0.00435 25.01
CDK1 0.03192 24.25 X X
ITGA6 0.00651 23.82 0.01105 23.35 X X X
DUSP6 0.00051 23.56 0.01223 22.08 X X
SLC20A1 0.00306 23.08 X
POLE2 0.00645 22.86 0.01939 22.31
CCNA2 0.02166 22.66 X X X
MCM6 0.00275 22.54
KRT19a´ 0.00000 22.50 0.00001 22.26
RFC3 0.00785 22.49
KRT34 0.00247 22.45
E2F7 0.04905 22.38 X
BRCA1 0.01466 22.25 0.02641 22.04 X X
PAK1 0.00399 22.24 0.02263 21.77 X X X X
HELLS 0.04234 22.22 X
ANGPTL4 0.01955 22.09 X X
ITGA4 0.00435 22.03 0.00371 22.08 X X X X
ACTA2 0.01071 21.91 0.02904 21.68 X
CCND1 0.00041 21.90 X X X
HOXA11 0.00279 21.88 0.00047 22.31
ITGA3 0.00146 21.69 X X X
FZD1 0.00697 21.58 0.00048 22.06 X
POLA2 0.02091 21.51 0.00795 21.66
ITGB5 0.03518 21.53 X X X X
ANXA4 0.02022 21.53 X
TIMP3a´aˆ 0.01839 21.57 X X X X
BCL2L10 0.00814 21.58 X
SMAD9 0.01991 21.61
IGF2BP3 0.02094 21.62 X
C5 0.01257 21.68 X X X X X
TGFBR3 0.04598 21.82 X X X X
ANGPTL2 0.02817 21.84
FAS 0.03925 21.85 X X X X X
LAMB1 0.03736 21.91 X X
TNFRSF19 0.02307 22.26 X
PDGFD 0.01484 23.19 X X
MMP10a´ 0.01030 23.91 X
IL13RA2 0.04783 23.64 X
CCNE2 0.01264 22.78 X X
PLAU 0.00713 22.42 X X X X
MELK 0.01473 22.41
ITGA2 0.01329 22.37 X X X X
CDC45 0.01108 22.30 X X
SPAG5 0.03517 22.16 ?
BRCA2 0.03864 21.96 X X X
E2F8 0.02061 21.85 X
MMP3 0.02542 21.84 X X X
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Discussion
Cumulating evidences point to an important role for embryo-
endometrial dialogue in mediating the adhesion, invasion and
growth of the embryo during implantation and early development.
Well-known for rescuing the corpus luteum and maintaining the
production of progesterone, embryo-derived signals such as hCG
seem to orchestrate endometrial adaptation to the implantation of
the newly formed embryo as well [22], but little is known about the
involved pathways and the underlying mechanisms. Human CG is
quite known, for instance, for stimulating cytokine/chemokine
production by endometrial epithelial and stromal cells and playing
direct and indirect roles in human ESC decidualization [17] and
angiogenesis in human endothelial cells [19,23,55]. It is unclear if
hCG is involved in blastocyst attachment in humans. However, it
may have an indirect role, as suggested by our and other studies,
and act via the modulation of human epithelial cell receptivity/
responsiveness to other major embryonic signals such as IL1 [56].
A recent study demonstrated that the expression of b3-integrin-
subunit, a cell adhesion mediator and marker of uterine receptivity
[57], on the surface of human endometrial epithelial cells could be
up-regulated by coculture with a human preimplantation embryo
and blocked by anti-IL1 antibody [35]. Another study showed that
the expression of trophinin, which mediates cell adhesion by
homophilic binding, and the ability for apical cell adhesion with
trophinin-expressing human trophoblastic cells are increased in
presence of hCG associated with IL1b [58].
The presence of LHCG receptor in various endometrial cell
types [15,16] makes plausible that hCG has a broad spectrum of
endometrial cell targets. After the intrusion of the embryo through
the luminal endometrial epithelium, trophoblastic cells are in close
contact with different maternal stromal cell types [59]. To achieve
a successful pregnancy, an appropriate cross-talk between
embryonic and maternal cells must therefore take place, where
numerous embryo- as well as maternal-derived factors including
steroid hormones, matrix degrading enzymes, integrins, cytokines,
chemokines and growth factors could be involved [60,61].
Our previous studies revealed a new mechanism by which hCG
can target different human endometrial cell types, including
epithelial and stromal cells, to modulate their receptivity to IL1, an
early potent embryonic signal, and amplify thereby the release of
immune and angiogenic factors [23,42]. In the present study, we
further showed that hCG acts on ESCs, either alone or via the
modulation of the IL1-mediated cell responsiveness, to regulate
numerous relevant genes involved in cell signaling, proliferation,
apoptosis, immune modulation, tissue remodeling and angiogen-
esis, which are highly relevant mechanisms underlying the
implantation process and the modulation of the immune response
around the implanting embryo. Some of the genes were known for
playing important roles in the various embryo implantation stages,
but many genes were not known for being possibly involved and
regulated by hCG or hCG/IL1B synergism.
MCPs were among the most significantly induced immune
factors in ESCs in response to hCG and IL1B. hCG amplified the
IL1B-induced expression of MCP1, 2 and 3. These chemokines
are involved in the recruitment of monocytes/macrophages, T
cells and NK cells into inflammatory sites [62,63]. Moreover,
MCPs stimulate angiogenesis, either directly via MCP1-induced
protein (MCPIP) or indirectly via their activation of immune cells
such as NK cells and macrophages, which are known for releasing
growth and angiogenic factors [64]. Interestingly, the current
micro-array data are in keeping with our previous findings of an
increased IL1B-mediated secretion of MCP1 in human ESCs from
the implantation window following hCG treatment [23] and
consistent with a possible role for MCPs in embryo implantation.
Actually, macrophages contribute to decidualization and implan-
tation and remain abundant at the implantation site throughout
pregnancy [65,66], and trophoblastic cells were shown to regulate
human monocyte migration and differentiation [67]. However,
uterine macrophages do not appear to impair the growth of the
semi-allogeneic embryo. They rather seem to play a protective role
against possible infections, maintain immune tolerance toward
trophoblastic antigens, mediate trophoblast invasion and support
embryonic growth [68]. This strengthens the relevance of our
findings and broadens the spectrum of hCG’s impact on early
embryonic growth and development.
VCAM1, an adhesion molecule of endothelial cells playing an
important role in immune cell trafficking [69], appeared to be up-
regulated by hCG or IL1B, but significantly by hCG and IL1B in
ESCs. During pregnancy, the few available reports suggest a
possible role for VCAM1. The expression of this adhesion
molecule is strongly induced in the endothelium of early pregnant
sheep endometrium [70] and decreases in fetal membranes with
advancing gestational age [71]. However, its role in human
pregnancy and during embryo implantation remains to be
elucidated.
Many other cytokines including IL6, CCL5 (RANTES) and
VEGFC appeared to be targeted by hCG and IL1B synergistic
action. These pluripotent factors are quite known for being
involved in the regulation of immune response, cell proliferation,
tissue remodeling and angiogenesis. First identified as a promoter
of B-cell differentiation and antibody production, IL6 is nowadays
Table 4. Cont.
Gene
p-value
hCG/IL1
FC
hCG/IL1
p-value
MM/IL1
FC
MM/IL1
p-value
hCG/MM
FC
hCG/MM
IPA
Pf.
IPA
Im.
IPA
Rm.
IPA
CS.
IPA
Ap.
IPA
Ag.
MCM5 0.01884 21.79
MCM3 0.02412 21.62
ORC1 0.00293 21.60
PCNA 0.02189 21.59 X X
E2F1 0.00984 21.55 X X X X
IL1Aa´ 0.02429 21.52 X X X X X X
FOSL1 0.01092 21.50 X X X
a´/aˆReal-time PCR/ ELISA validation performed
Pf, proliferation; Im, immune functions; Rm, tissue remodeling; CS, cell signaling; Ap, apoptosis; Ag, angiogenesis
doi:10.1371/journal.pone.0064829.t004
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Table 5. Name of down-regulated genes.
RefSeq Gene symbol Genes name
NM_004956 ETV1 ets variant 1
NM_002153 HSD17B2 hydroxysteroid (17-beta) dehydrogenase 2
NM_032211 LOXL4 lysyl oxidase-like 4
NM_001786 CDK1 cyclin-dependent kinase 1
NM_000210 ITGA6 integrin, alpha 6
NM_001946 DUSP6 dual specificity phosphatase 6
NM_005415 SLC20A1 solute carrier family 20 (phosphate transporter), member 20
NM_002692 POLE2 polymerase (DNA directed), epsilon 2 (p59 subunit)
NM_001237 CCNA2 cyclin A2
NM_005915 MCM6 minichromosome maintenance complex component 6
NM_002276 KRT19 keratin 19
NM_002915 RFC3 replication factor C (activator 1) 3, 38kDa
NM_021013 KRT34 keratin 34
NM_203394 E2F7 E2F transcription factor 7
NR_027676 BRCA1 breast cancer 1, early onset
NM_001128620 PAK1 p21 protein (Cdc42/Rac)-activated kinase 1
NM_018063 HELLS helicase, lymphoid-specific
NM_139314 ANGPTL4 angiopoietin-like 4
NM_000885 ITGA4 integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor)
NM_001141945 ACTA2 actin, alpha 2, smooth muscle, aorta
NM_053056 CCND1 cyclin D1
NM_005523 HOXA11 homeobox A11
NM_002204 ITGA3 integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor)
NM_003505 FZD1 frizzled homolog 1 (Drosophila)
NM_002689 POLA2 polymerase (DNA directed), alpha 2 (70kD subunit)
NM_002213 ITGB5 integrin, beta 5
NM_001153 ANXA4 annexin A4
NM_000362 TIMP3 TIMP metallopeptidase inhibitor 3
NM_020396 BCL2L10 BCL2-like 10 (apoptosis facilitator)
NM_001127217 SMAD9 SMAD family member 9
NM_006547 IGF2BP3 insulin-like growth factor 2 mRNA binding protein 3
NM_001735 C5 complement component 5
NM_003243 TGFBR3 transforming growth factor, beta receptor III
NM_012098 ANGPTL2 angiopoietin-like 2
NM_000043 FAS Fas (TNF receptor superfamily, member 6)
NM_002291 LAMB1 laminin, beta 1
NM_148957 TNFRSF19 tumor necrosis factor receptor superfamily, member 19
NM_025208 PDGFD platelet derived growth factor D
NM_002425 MMP10 matrix metallopeptidase 10 (stromelysin 2)
NM_000640 IL13RA2 interleukin 13 receptor, alpha 2
NM_057749 CCNE2 cyclin E2
NM_002658 PLAU plasminogen activator, urokinase
NM_014791 MELK maternal embryonic leucine zipper kinase
NM_002203 ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)
NM_001178010 CDC45 cell division cycle 45 homolog (S. cerevisiae)
NM_006461 SPAG5 sperm associated antigen 5
NM_000059 BRCA2 breast cancer 2, early onset
NM_024680 E2F8 E2F transcription factor 8
NM_002422 MMP3 matrix metallopeptidase 3 (stromelysin 1, progelatinase)
NM_006739 MCM5 minichromosome maintenance complex component 5
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known as a pleiotropic cytokine that regulates cell growth,
angiogenesis, inflammation and hematopoiesis [72]. IL6 expres-
sion was described in human granulosa and theca cells,
endometrium and pre-implantation embryo [73]. Also, habitual
abortion in women is associated with a decrease in expression of
IL1B and IL6 [74], suggesting a role for these cytokines in the
maintenance of pregnancy. A growing body of evidence implicates
CCL5 in the induction of tolerance at immune-privileged sites.
This cytokine seems to suppress maternal allogeneic responses,
which is necessary for successful implantation [75,76,77,78].
VEGFC is primarily a potent angiogenic growth factor and may
play an important role in embryonic cell growth. However, it was
described recently as an immune modulator that induces immune
tolerance in murine tumor cells [79]. Therefore, these hCG/IL1B-
induced biological properties in endometrial cells may represent a
relevant mechanism involved in the immune tolerance of the
implanting embryo within the uterine maternal host. This is in
keeping with a previous study reporting that in vivo infusion of
IL1B and hCG induces endometrial changes that mimic early
pregnancy events in the baboon and lead to the development of an
immunotolerant environment [80].
Invasion of the trophoblast into the endometrium requires a
delicate balance between tissue degradation and maintenance.
Up-regulation of MMP9 expression in endometrial cells by IL1B
in human endometrial cells [81] and secretion by cultured first
trimester human trophoblastic cells and fibroblasts has been
demonstrated [82]. In addition, the expression of MMPs
correlated with the invasive potential of human trophoblast cells
[82]. Our micro-array data and qRT-PCR validation revealed the
regulation of several tissue remodeling mediators such as MMP9,
TIMP3 and KRT19. MMP9 was significantly up-regulated by
IL1B in ESCs and hCG seemed to moderate this action, which,
however, remained significant compared to non-stimulated cells.
TIMP3, a natural tissue inhibitor of MMPs [83] was down-
regulated by IL1B either in the presence or the absence of hCG.
The reduction of TIMP3 expression levels, combined with the
increased expression of MMP9, may create an imbalance that
favors tissue matrix proteolysis and embryo implantation. How-
ever, the recent literature reporting that TIMP3 induces apoptosis,
inhibits angiogenesis and impedes cell migration [84] makes highly
relevant our present findings, considering the crucial importance
of embryonic cell survival, proliferation and migration for the
establishment of early pregnancy. Interestingly, KRT19, a
molecule associated with embryonic placenta development [54]
was found to be significantly inhibited by IL1B and more by IL1B
combined with hCG. KRT19 is an intermediate filament protein
and an epigenetically regulated tumor suppressor gene down-
regulated in several cancerous tumors [85]. Also, down-regulation
of KRT19 in human oral squamous cell carcinoma lines increases
Table 5. Cont.
RefSeq Gene symbol Genes name
NM_002388 MCM3 minichromosome maintenance complex component 3
NM_004153 ORC1 origin recognition complex, subunit 1
NM_002592 PCNA proliferating cell nuclear antigen
NM_005225 E2F1 E2F transcription factor 1
NM_000575 IL1A interleukin 1, alpha
NM_005438 FOSL1 FOS-like antigen 1
doi:10.1371/journal.pone.0064829.t005
Figure 3. hCG modulates MCPs’ mRNA expression in ESCs.
Confluent ESC cultures were incubated with minimal medium (MM)
(control) or hCG (100 ng/mL) for 24 h before being exposed or not to
IL1B (0.1 ng/mL) for additional 24 h. Total RNA was extracted and
reverse transcribed. CCL2, CCL8, CCL7 and GAPDH (internal control)
mRNA levels were quantified by real-time PCR. CCL2 (A), CCL8 (B) and
CCL7 (C) mRNA ratio was then determined following normalization to
GAPDH mRNA. Data were from ESC cultures issued from 7 different
subjects and expressed as fold change (FC) over control (ratio of CCL2,
CCL8 or CCL7 mRNA levels found in cells incubated with IL1B, hCG or
hCG/ILB to those found in cells incubated with MM for an equivalent
period of time). *P,0.05, *** P,0.001 relative to MM; {P,0.05,
{{{P,0.001 relative to cells stimulated with an equivalent concentra-
tion of hCG; +P,0.05 relative to cells stimulated with an equivalent
concentration of IL1B. Data were obtained with ESC cultures issued
from 7 different subjects (the 3 cultures used for microarray analysis and
4 additional cultures).
doi:10.1371/journal.pone.0064829.g003
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the invasive potential [86], but no other previous studies showed
any eventual relationship with the invasive capacity of embryonic
cells.
Micro-array and qRT-PCR validation data further revealed a
synergistic interaction between hCG and IL1B to induce PTGS2,
which is a rate limiting enzyme for PG synthesis. This is quite
relevant considering the well-documented role of PGs as key
regulators of female reproductive tract functions, including
ovulation, menstruation and myometrial contractility, and vascu-
lar permeability and angiogenesis at the implantation site
[87,88,89].
Interestingly, validation of the expression of some major selected
genes at the protein level corroborates the combined role of hCG
and IL1B in the modulation of angiogenic, immune and tissue
remodeling functions of ESCs. Actually, assessment of protein
secretion showed that hCG and IL1B synergistically induced
CCL2 and VEGFC, inhibited TIMP3 and moderate the IL1B-
induced MMP9.
Our previous studies showed that hCG down-regulates the
IL1B-induced increase in IL1R2 and IL1RN in human ESCs and
further enhances the IL1B-induced increase in IL1R1, thereby
amplifying in vitro the release of angiogenic activity [23].
Surprisingly, the results of the current micro-array analysis showed
a broader spectrum of regulation encompassing other IL1 family
members, and suggest a possible modulation of endometrial cell
responsiveness to IL1 family. In fact, hCG appeared to potentiate
the IL1B-induced expression of IL1R1L (IL33R) and IL18R and
to moderate, on the other hand, the expression of endogenous
IL33, IL18, IL1A and IL1B in ESCs. Nonetheless, the expression
of IL1 isoforms was still up-regulated despite the down-regulatory
effect of hCG. These results indicate a possible mechanism by
which hCG may induce immunotropism and prevent undue local
expression of proinflammatory cytokines, as excessive production
levels may be associated with repeated miscarriage and fetal
growth retardation [90].
It is noteworthy that according to the recent literature, hCG has
been shown to be produced by human endometrial epithelial cells
Figure 4. hCG modulates the IL1B-mediated mRNA expression of immune modulating, adhesion, growth, angiogenic and tissue
remodeling factors in ESCs. Confluent ESC cultures were incubated with minimal medium (MM) (control) or hCG (100 ng/mL) for 24 h before
being exposed or not to IL1B (0.1 ng/mL) for additional 24 h. Total RNA was extracted and reverse transcribed, and mRNA levels were then quantified
by qRT-PCR. VCAM1 (A), IL6 (B), CCL5 (C), PTGS2 (D), VEGFC (E), MMP9 (F), TIMP3 (G) and KRT19 (H) mRNA ratio was then determined following
normalization to GAPDH mRNA (internal control). Data were from ESC cultures issued from 7 different subjects and expressed as fold change (FC)
over control (ratio of VCAM1, IL6, CCL5, PTGS2, VEGFC, MMP9, TIMP3 or KRT19 mRNA levels found in cells incubated with IL1B, hCG or hCG/ILB to
those found in cells incubated with MM for an equivalent period of time). *P,0.05, **P,0.01, *** P,0.001 relative to MM; {P,0.05, {{P,0.01,
{{{P,0.001 relative to cells stimulated with an equivalent concentration of hCG; +P,0.05 relative to cells stimulated with an equivalent
concentration of IL1B. Data were obtained with ESC cultures issued from 7 different subjects (the 3 cultures used for microarray analysis and 4
additional cultures).
doi:10.1371/journal.pone.0064829.g004
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Figure 5. hCGmodulates IL1B effects on the expression of IL1 family members in ESCs. Confluent ESC cultures were incubated with minimal
medium (MM) or hCG (100 ng/mL) for 24 h before being exposed or not to IL1B (0.1 ng/mL) for additional 24 h. Total RNA was extracted and reverse
transcribed, and mRNA levels were then quantified by qRT-PCR. IL1A (A), IL1B (D), IL1RL1 (B), IL18R1 (E), IL33 (C) and IL18 (F) mRNA ratio was then
determined following normalization to GAPDH mRNA (internal control). Data were from ESC cultures issued from 7 different subjects and expressed as
fold change (FC) over control (ratio of IL1A, IL1B, IL1RL1, IL18R1, IL33 or IL18 mRNA levels found in cells incubated with IL1B, hCG or hCG/ILB to those
found in cells incubated with MM for an equivalent period of time). *P,0.05, **P,0.01, *** P,0.001 relative to MM; {P,0.05, {{{P,0.001 relative to
cells stimulated with an equivalent concentration of hCG; ++P,0.01 relative to cells stimulated with an equivalent concentration of IL1B. Data were
obtained with ESC cultures issued from 7 different subjects (the 3 cultures used for microarray analysis and 4 additional cultures).
doi:10.1371/journal.pone.0064829.g005
Figure 6. hCGmodulates the expression of immune, angiogenic and tissue remodeling factors in ESCs at the protein level. Confluent
ESC cultures were incubated with minimal medium (MM) or hCG (100 ng/mL) for 24 h before being exposed or not to IL1B (0.1 ng/mL) for additional
24 h. Supernatant was collected and soluble proteins CCL2 (A) CCL5 (B) VEGFC (C) TIMP3 (D) MMP9 (E) were then quantified by ELISA. Data were from
ESC cultures issued from 4 different subjects and expressed in pg/mL. *P,0.05, *** P,0.001 relative to MM; {{P,0.01, {{{P,0.001 relative to cells
stimulated with an equivalent concentration of hCG; +P,0.05, +++P,0.001 relative to cells stimulated with an equivalent concentration of IL1B.
doi:10.1371/journal.pone.0064829.g006
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in the luteal phase [12]. Indeed, endogenous endometrial hCG
may, though produced at low quantities, have a role in in embryo
implantation and the hCG-mediated growth promoting effects,
but this is still to be demonstrated.
In conclusion, our study showed that hCG induces major
changes in human ESC phenotype and deeply modulates their
responsiveness to a proinflammatory, but a growth mediator and a
potent embryonic signal such as IL1B. Generally via synergistic
stimulatory or inhibitory mechanisms, hCG induces significant
alterations in the expression of genes known for being involved or
having the potential to play an important role in embryonic
implantation and growth and the modulation of the immune
response around the implanting blastocyst. Furthermore, our study
revealed that the modulation of endometrial cell receptivity via
hCG is not limited to IL1 receptors’ agonists and antagonists, but
also extends to other IL1 family members, which share numerous
growth-promoting, immune-modulating and signaling pathways.
This, together with our previous data showing that hCG can
similarly target different endometrial cell types, strengthens the
relevance of such a modulatory mechanism for implantation and
early embryonic growth within the host maternal endometrial
tissue and further suggests that hCG plays an important role in the
establishment of a receptive endometrial phenotype.
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